Haemonetics (HAE) Aandeel Koers
Haemonetics Koers
In de afgelopen 19 jaar liet Haemonetics de omzet jaarlijks met 5,9% groeien tot 1,33 Miljard USD. De winst per aandeel is de afgelopen 19 jaar met 4,5% per jaar gegroeid. Bij Haemonetics is de nettowinstmarge met 7,3% ten opzichte van 4,4% enkele jaren geleden gestegen. Het consensus-koersdoel voor Haemonetics op 12 maanden bedraagt 96,00 USD, circa 18,3% onder de huidige koers. Van de 15 analisten geven 12 het aandeel een koopadvies — per saldo een Kopen-consensus.
Haemonetics aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Haemonetics bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Haemonetics
The business model of Haemonetics Corp focuses on providing innovative and comprehensive solutions for blood and plasma collection, as well as transfusion medicine. This global healthcare company specializes in the development and manufacturing of devices and software that aid in blood management, including blood processing systems, information technology solutions, and donor management software. Haemonetics Corp aims to improve patient outcomes and enhance operational efficiency in blood and plasma centers, hospitals, and other healthcare settings worldwide through its integrated offerings.
Haemonetics Corp is primarily active in the healthcare industry.
Haemonetics Corp has several key competitors in the market. Some of its main competitors include Fresenius Kabi AG, B. Braun Melsungen AG, and Terumo Corporation. These companies also operate in the healthcare industry, specifically in the blood management and hematology sectors. However, Haemonetics Corp distinguishes itself through its innovative medical devices and advanced solutions, making it a formidable competitor in the market.
Haemonetics Corp is a renowned global healthcare company specializing in blood management solutions. Founded in 1971, Haemonetics has been actively shaping the medical industry for over five decades. The company's core focus lies in providing innovative devices, software, and services to enhance blood and plasma collection, processing, and transfusion. Haemonetics serves a wide range of healthcare providers, including blood banks, hospitals, and plasma fractionators. With its commitment to advancing patient care and blood safety, Haemonetics has become a trusted partner for healthcare institutions worldwide. Through continuous research and development, the company remains at the forefront of the industry, constantly expanding its product portfolio and improving blood management practices.
Haemonetics Corp has achieved several significant milestones throughout its history. One notable achievement is the development and introduction of the industry's first fully automated blood processing system, called PCS2. This innovative system has revolutionized the way blood components are collected, processed, and stored. Another important milestone for Haemonetics Corp is the acquisition of Pall Corporation's blood transfusion and filtration business in 2012, which expanded their product portfolio and global presence. Furthermore, the company has continuously focused on research and development to enhance its offerings, resulting in numerous product advancements and patents. Haemonetics Corp's commitment to innovation has solidified its position as a leading provider of blood management solutions.
Haemonetics Corp is primarily present in various countries and regions around the world. The company has a global presence and operates in several key markets including the United States, Europe, Asia-Pacific, and Latin America. It serves healthcare providers and blood banks in these regions, offering innovative blood management solutions for improved patient outcomes. Haemonetics Corp's commitment to expanding its operations internationally has allowed it to establish a strong foothold in the global healthcare industry.
Haemonetics Corp represents values of innovation, quality, and efficiency in the healthcare industry. The company is dedicated to providing advanced blood management solutions that improve patient outcomes and enhance safety. Haemonetics Corp embraces a corporate philosophy centered around collaboration, customer focus, and continuous improvement. Their commitment to delivering cutting-edge technologies and services is reflected in their strong market position and global presence. With a focus on advancing the standard of care, Haemonetics Corp strives to make a positive impact on the lives of patients and healthcare providers alike.
Analisten hanteren momenteel een gemiddeld koersdoel van 95,40 USD voor het aandeel Haemonetics (mediaan: 96,00 USD), oftewel -18,9 % ten opzichte van de laatste koers. De consensus is gebaseerd op 15 analistenratings.
15 analisten beoordelen het aandeel Haemonetics momenteel: 12 adviseren kopen, 3 houden en 0 verkopen.
Omgezet tegen de huidige wisselkoers noteert het aandeel Haemonetics op 104,72 EUR (117,57 USD).
Het aandeel Haemonetics (HAE) is genoteerd aan 3 beurzen, waaronder: NYSE (HAE), Frankfurt (HAZ.F), München (HAZ.MU).
Haemonetics Corp is a leading global provider of innovative blood processing systems and medical devices for the healthcare and biotechnology industries. The company offers a wide range of products divided into three main business segments: Plasma, Blood, and Hospital. The Plasma division of Haemonetics Corp focuses on the development and manufacturing of systems for the collection, processing, and storage of plasma for use in life-saving therapies. These systems are specifically designed for blood donation services, plasma collection centers, and pharmaceutical manufacturers. The company has developed a number of innovative plasma separation systems such as PCS2 and PCS2 plus, which utilize the benefits of microprocessors to automate the processing process while reducing processing time. The Blood division of the company offers a range of devices and systems for blood processing, such as the Cell Saver System for blood transfusion during surgical procedures and the OrthoPAT Advance System for the collection and processing of autologous blood for use in orthopedic procedures. The company has also developed a variety of devices to support blood transfusions, such as the TEG Systems, which provides real-time information on blood clotting. Haemonetics Corp also focuses on developing innovative solutions for hospital departments and clinical facilities. The company offers solutions for blood and plasma collection in clinical facilities and hospitals, such as the TEG 5000 Thrombelastograph Hemostasis Analyzer System or the Cell Saver Elite System, which can be used directly during surgery. The company also provides solutions for patient data management and documentation, such as eAuto Blood Bank or SafeTrace Tx blood management software, to ensure better patient care and safety. Haemonetics Corp promotes the success of its business models through a strong market presence and effective management of distribution channels. Investments in research and development have contributed to the creation of innovative products and services that provide a competitive advantage. Overall, Haemonetics Corp is a leading provider of blood processing systems and medical devices that contribute to making the healthcare industry safer and more effective. The company has the ability to adapt to rapidly changing needs while maintaining a strong leadership position in the industry.
De omzet van Haemonetics bedraagt 1,33 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De winst van Haemonetics bedraagt 97,31 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Haemonetics bedraagt momenteel 55,22. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Haemonetics-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Haemonetics bedraagt momenteel 4,03. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Haemonetics-aandeel.
De Eulerpool Kwaliteitsscore voor Haemonetics is 3/10.
De ISIN van Haemonetics is US4050241003. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Haemonetics is 881782. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Haemonetics is HAE. Onder dit beurstickersymbool wordt het Haemonetics-aandeel op de beurs verhandeld.
Haemonetics aandeel
Haemonetics Peer Group
Haemonetics Ticker
Haemonetics FIGI
Alle fundamentals en diepgaande analyse van Haemonetics
Onze aandelenanalyse van het Haemonetics-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Haemonetics. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: